Literature DB >> 20177954

Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection.

Abdulrahman M Al-Muammar1, Tariq M Al-Mudhaiyan, Mohammed Al Otaibi, Ayman Abdo, Ahmed M Abu El-Asrar.   

Abstract

We report a case of Vogt-Koyanagi-Harada (VKH) disease in a 30-year-old patient who was receiving interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection. The intraocular inflammation responded to systemic corticosteroid and mycophenolate mofetil treatment. Physicians should be aware of the association between interferon-alpha and ribavirin therapy for hepatitis C virus infection and the development of VKH disease.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20177954     DOI： 10.1007/s10792-010-9357-0

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN： 0165-5701            Impact factor:   2.031


  10 in total

1.  Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats.

Authors:  K Yamaki; I Kondo; H Nakamura; M Miyano; S Konno; S Sakuragi
Journal:  Exp Eye Res       Date:  2000-10       Impact factor: 3.467

2.  Vogt-Koyanagi-Harada disease associated with interferon-A and ribavirin therapy for chronic hepatitis C infection.

Authors:  Konstantinos Papastathopoulos; Evridiki Bouzas; George Naoum; Ioannis Vergados; Sotirios Tsiodras
Journal:  J Infect       Date:  2005-06-13       Impact factor: 6.072

Review 3.  Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C.

Authors:  Akinori Kasahara; Atsushi Hiraide; Naruya Tomita; Hiromi Iwahashi; Akihisa Imagawa; Nobuyuki Ohguro; Shuji Yamamoto; Eiji Mita; Norio Hayashi
Journal:  J Gastroenterol       Date:  2004-11       Impact factor: 7.527

4.  Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C.

Authors:  Valérie Touitou; Bahram Bodaghi; Nathalie Cassoux; Thi Ha Chau Tran; Narsing A Rao; Patrice Cacoub; Phuc LeHoang
Journal:  Am J Ophthalmol       Date:  2005-11       Impact factor: 5.258

5.  Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view.

Authors:  R Pellicano; A Smedile; S Peyre; M Astegiano; G Saracco; R Bonardi; M Rizzetto
Journal:  Minerva Gastroenterol Dietol       Date:  2005-03

6.  Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy.

Authors:  D L Sylvestre; A R Disston; D P Bui
Journal:  J Viral Hepat       Date:  2003-11       Impact factor: 3.728

Review 7.  Vogt-Koyanagi-Harada syndrome.

Authors:  R S Moorthy; H Inomata; N A Rao
Journal:  Surv Ophthalmol       Date:  1995 Jan-Feb       Impact factor: 6.048

8.  Retinal complications during interferon therapy for chronic hepatitis C.

Authors:  T Kawano; M Shigehira; H Uto; T Nakama; J Kato; K Hayashi; T Maruyama; T Kuribayashi; T Chuman; T Futami; H Tsubouchi
Journal:  Am J Gastroenterol       Date:  1996-02       Impact factor: 10.864

9.  Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C.

Authors:  Damien Sene; Valerie Touitou; Bahram Bodaghi; David Saadoun; Gabriel Perlemuter; Nathalie Cassoux; Jean-Charles Piette; Phuc-Le Hoang; Patrice Cacoub
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

10.  Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword?

Authors:  Valerie Touitou; Damien Sene; Christine Fardeau; Thi-Huong-Du Boutin; Pierre Duhaut; Jean-Charles Piette; Phuc LeHoang; Patrice Cacoub; Bahram Bodaghi
Journal:  Int Ophthalmol       Date:  2007-02-23       Impact factor: 2.029
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.